161 related articles for article (PubMed ID: 19748743)
1. Monitoring risk: post marketing surveillance and signal detection.
Dart RC
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S26-32. PubMed ID: 19748743
[TBL] [Abstract][Full Text] [Related]
2. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.
Butler SF; Budman SH; Licari A; Cassidy TA; Lioy K; Dickinson J; Brownstein JS; Benneyan JC; Green TC; Katz N
Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1142-54. PubMed ID: 18932173
[TBL] [Abstract][Full Text] [Related]
3. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
[TBL] [Abstract][Full Text] [Related]
4. Risk management and post-marketing surveillance of CNS drugs.
Henningfield JE; Schuster CR
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S56-64. PubMed ID: 19767155
[TBL] [Abstract][Full Text] [Related]
5. [Post-marketing surveillance systems for psychoactive prescription drug abuse].
Nordmann S; Frauger E; Pauly V; Rouby F; Mallaret M; Micallef J; Thirion X
Therapie; 2011; 66(3):263-72. PubMed ID: 21819810
[TBL] [Abstract][Full Text] [Related]
6. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004.
Cicero TJ; Inciardi JA; Adams EH; Geller A; Senay EC; Woody GE; Muñoz A
Pharmacoepidemiol Drug Saf; 2005 Dec; 14(12):851-9. PubMed ID: 15892169
[TBL] [Abstract][Full Text] [Related]
7. The Diversion of Ultram, Ultracet, and generic tramadol HCL.
Inciardi JA; Cicero TJ; Munoz A; Adams EH; Geller A; Senay EC; Woody GE
J Addict Dis; 2006; 25(2):53-8. PubMed ID: 16785220
[TBL] [Abstract][Full Text] [Related]
8. Signal detection in post-marketing surveillance for controlled substances.
Dasgupta N; Schnoll SH
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S33-41. PubMed ID: 19616902
[TBL] [Abstract][Full Text] [Related]
9. Abuse deterrent formulations and the Controlled Substances Act (CSA).
Sapienza FL
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S23-30. PubMed ID: 16529882
[TBL] [Abstract][Full Text] [Related]
10. Risk management and post-marketing surveillance of CNS drugs: an introduction.
Balster RL; Johanson CE; Walsh SL
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S1-3. PubMed ID: 19744805
[No Abstract] [Full Text] [Related]
11. Introduction to College on Problems of Drug Dependence special conference on risk management and post-marketing surveillance of CNS drugs.
Schuster CR; Barthwell AG; Henningfield JE
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S4-8. PubMed ID: 19783381
[No Abstract] [Full Text] [Related]
12. Risk management of drug products and the U.S. Food and Drug Administration: evolution and context.
Leiderman DB
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S9-S13. PubMed ID: 19307069
[TBL] [Abstract][Full Text] [Related]
13. Integrating nine prescription opioid analgesics and/or four signal detection systems to summarize statewide prescription drug abuse in the United States in 2007.
Schneider MF; Bailey JE; Cicero TJ; Dart RC; Inciardi JA; Parrino M; Muñoz A
Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):778-90. PubMed ID: 19536784
[TBL] [Abstract][Full Text] [Related]
14. Active surveillance of abused and misused prescription opioids using poison center data: a pilot study and descriptive comparison.
Hughes AA; Bogdan GM; Dart RC
Clin Toxicol (Phila); 2007; 45(2):144-51. PubMed ID: 17364631
[TBL] [Abstract][Full Text] [Related]
15. Trends in the use and abuse of branded and generic extended release oxycodone and fentanyl products in the United States.
Cicero TJ; Inciardi JA; Surratt H
Drug Alcohol Depend; 2007 Dec; 91(2-3):115-20. PubMed ID: 17590285
[TBL] [Abstract][Full Text] [Related]
16. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
Wright C; Schnoll S; Bernstein D
Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
[TBL] [Abstract][Full Text] [Related]
17. Trends in opioid analgesic abuse and mortality in the United States.
Dart RC; Surratt HL; Cicero TJ; Parrino MW; Severtson SG; Bucher-Bartelson B; Green JL
N Engl J Med; 2015 Jan; 372(3):241-8. PubMed ID: 25587948
[TBL] [Abstract][Full Text] [Related]
18. Detecting signals of opioid analgesic abuse: application of a spatial mixed effect poisson regression model using data from a network of poison control centers.
Smith MY; Irish W; Wang J; Haddox JD; Dart RC
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1050-9. PubMed ID: 18803336
[TBL] [Abstract][Full Text] [Related]
19. OxyContin abuse and diversion and efforts to address the problem: highlights of a government report.
Government Accounting Office
J Pain Palliat Care Pharmacother; 2004; 18(3):109-13. PubMed ID: 15364638
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of efficacy of heartworm preventive products at the FDA.
Hampshire VA
Vet Parasitol; 2005 Oct; 133(2-3):191-5. PubMed ID: 16099105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
